New real-world data from Providence, Illumina (NASDAQ: ILMN), and Microsoft Research reveals that Comprehensive Genomic Profiling (CGP), when done early in a cancer patient's diagnosis, leads to ...

CGP identifies TP53 and SMAD4 mutations as negative prognostic markers, while PTEN mutations correlate with improved survival in CRC patients. Despite no significant survival advantage, CGP-guided ...

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses the latest advancements in HR+/HER2– breast cancer research, as well as the ...

RENTON, Wash. [Nov. 12, 2024] – New real-world data from Providence, Illumina (NASDAQ: ILMN), and Microsoft Research reveals that Comprehensive Genomic Profiling (CGP), when done early in a cancer ...

Precision medicines and personalized treatments are revolutionizing cancer therapy. Small molecules, biological agents, antibody-drug conjugates and cell-based therapies directed against specific ...

Accurate genomic profiling is essential for clinical decision-making and optimizing treatment recommendations. Tumor-only sequencing has been adopted by many laboratories to guide precision oncology ...

Led by a team from Buffalo, N.Y.-based Roswell Park Comprehensive Cancer Center, researchers have created the largest and most detailed profile of genetic mutations found in African American women ...

A new study published in Science Translational Medicine by researchers at The University of Texas MD Anderson Cancer Center ...

Mount Sinai scientists developed V2P, a powerful new AI tool that predicts how specific DNA mutations translate into disease, unlocking faster diagnoses and new targets for therapy.